This case–control study compared EcSOD polymorphisms at rs1799895 (Arg231Gly) of 235 pancreatic cancer patients to 265 controls, but failed to demonstrate any concordance between polymorphism and cancer risk [47]. This evidence concerns the gene SOD3 and pancreatic neoplasm.